companydata.dkcompanydata.dk

Daiichi Sankyo Nordics ApS: Financial statements 2024

CVR: 39371049

Source: annual report 2024, Danish Business Authority

01/04/2023 – 31/03/2024

Daiichi Sankyo Nordics ApS (CVR 39371049) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 57,381,295 and a net result of DKK 8,448,867 compared with DKK 2,350,138 the year before. That is an increase of 20% compared with the year before. Equity in the 2024 report amounted to DKK 14,056,215. The solvency ratio was 7.8%. The company had 26 employees in the financial year.

Gross Profit
DKK 57,381,295
Profit/Loss
DKK 8,448,867
Equity
DKK 14,056,215
Total Assets
DKK 181,341,726
Employees
26

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-57.4M8.4M14.1M26
2023-47.8M2.4M5.7M24
2022-35.6M46K3.4M22
2021-27.4M846K3.3M16
2020-20.6M1.2M2.5M16

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

About Daiichi Sankyo Nordics ApS

Daiichi Sankyo Nordics ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Daiichi Sankyo Oncology Nordics ApS. The management consists of Christophe Tiberghien. The board consists of Christophe Tiberghien, Jacob Wessel-Tolvig and Karin Margaretha Heisterberg. The company is owned by Daiichi Sankyo Oncology Europe GmbH. The company has 32 employees (2026). In 2026, the company reported a gross profit of DKK 83,558,930 and a net result of DKK 17,269,490 compared with DKK 9,020,707 the year before. Equity in the 2026 report amounted to DKK 40,346,412.

Source: annual report 2026, Danish Business Authority

Other financial years